Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients

NCT00050232 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
96
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Avanir Pharmaceuticals